In the present study, we hypothesized that treatment of insomnia with CBT-I would reduce expression of p16INK4a in peripheral blood mononuclear cells (PBMCs) compared to a sleep education therapy (SET), an active comparator condition. Here, CDKN2A is linked to insomnia.